ALK-Abello A/S
CSE:ALK B
ALK-Abello A/S
CSE:ALK B
Price:
202
DKK
-0.88%
Market Closed
Market Cap:
kr40.9B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
ALK-Abello A/S
CSE:ALK B
|
DK |
|
R
|
Romerike Sparebank
OSE:ROMER
|
NO |
|
Buhler Industries Inc
TSX:BUI
|
CA |
|
EverGen Infrastructure Corp
XTSX:EVGN
|
CA |
|
AB Science SA
PAR:AB
|
FR |
|
Zhonghua Gas Holdings Ltd
HKEX:8246
|
HK |
|
A
|
Aksharchem (India) Ltd
NSE:AKSHARCHEM
|
IN |
|
Ems Chemie Holding AG
SIX:EMSN
|
CH |
|
W
|
Wuxi Online Offline Communication Information Technology Co Ltd
SZSE:300959
|
CN |
|
S
|
SMTrack Bhd
KLSE:SMTRACK
|
MY |
|
Glory Land Company Ltd
HKEX:2329
|
CN |
|
Accordant Group Ltd
NZX:AGL
|
NZ |
Multiples-Based Value
The Multiples-Based Value of one
ALK B
stock under the Base Case scenario is
hidden
DKK.
Compared to the current market price of 202 DKK,
ALK-Abello A/S
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ALK B Multiples-Based Value
LOCKED
Multiples Across Competitors
ALK B Competitors Multiples
ALK-Abello A/S Competitors
ALK-Abello A/S Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| DK |
|
ALK-Abello A/S
CSE:ALK B
|
44.8B DKK | 7.1 | 37.4 | 22.1 | 26.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
837.7B USD | 12.9 | 40.6 | 27.4 | 29.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
583.9B USD | 6.2 | 21.8 | 15.1 | 18.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.3 | 11.5 | 12.9 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
228B GBP | 5.2 | 29.9 | 16.5 | 23.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
292.3B USD | 4.5 | 16 | 9.9 | 12.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
228.6B CHF | 5.3 | 21.2 | 13.1 | 16.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.3 | 10 | 7.5 | 8.7 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
157.9B USD | 2.5 | 20.3 | 7.8 | 10.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120.2B USD | 2.5 | 17.1 | 7.2 | 8.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
